Patent · US Active

Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors

US8673924B2 · kind B2 · utility

10Cited by

8References

25Claims

0Family size

Assignees

Merck Sharp & Dohme LLC · US
PHARMACOPEIA, LLC · US

Inventors

Timothy J. Guzi · Chatham, US
Kamil Paruch · Garwood, US
Michael P. Dwyer · Scotch Plains, US
Ronald J. Doll · Maplewood, US
Viyyoor M. Girijavallabhan · Parsippany, US
Alan K. Mallams · Hackettstown, US
Carmen Alvarez · Roselle Park, US
Kartik M. Keertikar · Plainsboro, US
Jocelyn Rivera · Monmouth Junction, US
Tin-Yau Chan · Edison, US
Vincent S. Madison · Mountain Lakes, US
Thierry O. Fischmann · Scotch Plains, US
Lawrence Wayne Dillard · Yardley, US
Vinh D. Tran · Willow View Lane, US
Zhenmin He · Shanghai, CN
Ray Anthony James · Bristol, US
Haengsoon Park · Plainsboro, US
Vidyadhar Paradkar · Somerville, US
Douglas W. Hobbs · Yardley, US
Paul Kirschmeier · Berkeley Heights, US
Rajat Bannerji · Morristown, US

Key dates

Filing date	Apr 20, 2007
Grant date	Mar 18, 2014
Priority date	—
Expiry date	Oct 21, 2028

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P43/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

In its many embodiments, the present invention provides a method of inhibiting one or more cyclin dependent kinases in a patient comprising administering to said patient a therapeutically effective amount of at least one pyrazolo[1,5-a]pyrimidine compound or a pharmaceutical composition comprising such compound, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions. An example pyrazolo[1,5-a]pyrimidine compound useful in the present invention is shown below:

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.